# Labcorp (LH) Financial Model Free Excel 3-statement financial model and company analysis for Labcorp. - Canonical: https://finamodel.com/companies/labcorp - Industry: Healthcare Services - Downloadable model: Yes - Excel download: https://finamodel.com/company-models/LH.xlsx ## Model Purpose This model provides a comprehensive equity valuation and scenario planning tool for Labcorp (LH) to assess how changes in diagnostic testing volumes, Medicare pricing dynamics, and Biopharma Laboratory Services backlog conversion impact the company's intrinsic value and free cash flow generation. ## Company Overview Laboratory Corporation of America Holdings (Labcorp) is a global life sciences company that provides comprehensive clinical laboratory and end-to-end drug development services. The company operates a massive infrastructure of testing facilities, patient service centres, and central laboratories that serve doctors, hospitals, pharmaceutical companies, and researchers. The business operates through two primary segments: Diagnostics Laboratories (Dx), which accounts for approximately 77% of total revenue, and Biopharma Laboratory Services (BLS), which accounts for the remaining 23%. Geographically, the Diagnostics business is heavily concentrated in the United States, while the BLS segment operates on a global scale to support international clinical trials. Labcorp operates an asset-heavy, high fixed-cost leverage business model where profitability is highly sensitive to testing volumes and requisition throughput. Competitively, Labcorp operates in a virtual duopoly in the US independent clinical laboratory market alongside Quest Diagnostics, while competing with global Contract Research Organisations (CROs) in its BLS segment. A major recent corporate event was the mid-2023 spin-off of its Clinical Development business (now Fortrea, ticker: FTRE), which transitioned Labcorp's reporting structure to focus purely on Central Labs and Early Development within its BLS segment. Furthermore, the company has been an active acquirer, purchasing select assets from Invitae and executing numerous hospital outreach laboratory acquisitions throughout 2024 and 2025. ## Revenue Deep Dive ### Diagnostics Laboratories (Dx) - **Segment name:** Diagnostics Laboratories (Dx) - **Revenue driver formula:** Requisition Volume x Revenue per Requisition (Price/Mix) - **Historical growth rate:** 3-5% organic CAGR (excluding the volatility of COVID-19 testing) - **Key growth levers and headwinds:** Growth is driven by hospital outreach acquisitions, an aging population, and the introduction of high-value specialty testing (oncology, women's health, neurology). The primary headwind is reimbursement pressure from commercial payers and statutory Medicare cuts under the Protecting Access to Medicare Act (PAMA). - **Pricing dynamics:** Highly regulated and contractual. Medicare and Medicaid set statutory fee schedules, while commercial pricing is negotiated via long-term contracts with major health insurers. - **Revenue recognition notes:** Recognised at a point in time when the testing process is complete and results are reported to the ordering physician. Revenue is recorded net of estimated uncollectible amounts (implicit price concessions). - **Seasonality:** Q1 is typically the weakest quarter due to winter weather disrupting patient visits and the resetting of patient deductibles. Q3 and Q4 are generally stronger. ### Biopharma Laboratory Services (BLS) - **Segment name:** Biopharma Laboratory Services (BLS) - **Revenue driver formula:** Beginning Backlog x Backlog Conversion Rate (supported by Net Orders and Book-to-Bill ratio) - **Historical growth rate:** 5-8% CAGR - **Key growth levers and headwinds:** Driven by global pharmaceutical R&D spending, biotech funding environments, and the increasing complexity of clinical trials requiring advanced central laboratory testing. Headwinds include trial cancellations and foreign exchange volatility. - **Pricing dynamics:** Contractual, based on long-term master service agreements with pharmaceutical and biotechnology sponsors. - **Revenue recognition notes:** Recognised over time as services are performed, using an input method based on costs incurred relative to total estimated costs. - **Seasonality:** Less seasonal than Diagnostics, but Q4 often sees a slight uptick due to year-end budget utilisation by pharmaceutical clients. ## Cost Structure ### Variable Costs / COGS - **Line-by-line breakdown:** Personnel costs (phlebotomists, laboratory technicians, scientists), laboratory supplies, reagents, and logistics/transportation costs (courier networks). - **Gross margin range:** 27% to 30% over the last 5 years. - **Key input costs and commodity exposures:** Labour wage inflation is the most significant input cost, followed by the cost of proprietary testing reagents and fuel costs for the logistics fleet. - **How COGS scales with revenue:** High operating leverage. The infrastructure (labs, equipment, courier routes) represents a significant fixed cost base. Incremental testing volume drops through to gross margin at a very high rate. ### Operating Expenses - **R&D:** Not broken out as a traditional percentage of revenue; innovation costs are largely embedded in COGS and SG&A as the company develops new assays and validates tests. - **SG&A:** Typically 13% to 15% of revenue. This includes billing and collection operations, sales force compensation, and corporate administrative overhead. It is highly headcount-driven. - **Depreciation & Amortisation:** Typically 4% to 5% of revenue, split heavily towards amortisation of intangibles due to the company's serial acquisition strategy. - **Stock-Based Compensation:** Approximately 0.5% to 1.0% of revenue. - **Restructuring / one-time charges:** Frequent and material. Labcorp regularly reports "LaunchPad" initiative costs, facility consolidation expenses, and acquisition integration charges. ### Margin Profile - **Gross margin:** 27-30% - **EBITDA margin:** 18-21% (Adjusted) - **Operating margin:** 14-16% (Adjusted) - **Net margin:** 8-10% (Adjusted) - **Margin trend:** Margins compressed slightly following the peak of high-margin COVID-19 testing but are currently expanding due to LaunchPad cost savings and the integration of higher-margin specialty testing acquisitions. ## Balance Sheet Structure - **Total assets:** Approximately $20 billion. - **Key asset categories:** Goodwill, intangible assets, accounts receivable, and property, plant, and equipment. - **Goodwill & intangibles as % of total assets:** Approximately 50-55%, reflecting a long history of acquisitions including Covance and numerous regional laboratories. - **Working capital profile:** - **Days Sales Outstanding (DSO):** 45 to 55 days. Billing complexity with third-party payers makes this a critical metric. - **Days Inventory Outstanding (DIO):** 15 to 20 days (primarily lab supplies and reagents). - **Days Payable Outstanding (DPO):** 35 to 45 days. - **Net working capital as % of revenue:** Approximately 5% to 8%. - **Is working capital positive or negative?** Positive. The company requires working capital to fund growth, primarily due to the extended collection cycle from healthcare payers. - **PP&E:** Approximately $2.5 billion. Consists of laboratory equipment, central lab facilities, and patient service centre build-outs. Maintenance capex is roughly half of total capex. - **Right-of-use assets / operating leases:** Material. Approximately $1.2 billion, representing leases for thousands of patient service centres and laboratory facilities. ## Capital Expenditure & Investment - **Capex as % of revenue:** 3.5% to 4.5%. - **Maintenance capex vs. growth capex:** Estimated at 50% maintenance (replacing lab equipment, facility upkeep) and 50% growth (new central lab facilities, digital pathology investments). - **Major capex programmes underway:** A strategic investment to build a modern, 500,000 square foot Central Laboratory facility in Indiana, announced in early 2026. - **Capitalised software / development costs:** Moderate, primarily related to customer-facing digital portals and internal laboratory information systems. - **M&A pattern:** Serial bolt-on acquirer. The company routinely buys hospital outreach laboratories and regional independent labs to build density, alongside targeted specialty testing acquisitions (e.g., Invitae assets). - **Typical acquisition multiple paid:** 8x to 12x EV/EBITDA post-synergies. ## Debt & Capital Structure - **Total debt:** $5.58 billion (as of year-end 2025). - **Net debt:** Approximately $5.05 billion. - **Debt/EBITDA ratio:** Currently around 1.8x to 2.0x. The company targets a leverage ratio below 2.5x. - **Credit rating:** Investment grade (Baa2/BBB). - **Key debt instruments:** Primarily unsecured senior notes with staggered maturities, supported by a revolving credit facility. - **Maturity profile:** Well-laddered. The company actively pre-funds near-term maturities, as seen in late 2024 and 2025. - **Interest rate profile:** Predominantly fixed-rate bonds. Weighted average cost of debt is approximately 4.5% to 5.0%. - **Covenants:** Standard investment-grade covenants, primarily a maximum leverage ratio. - **Share repurchase programme:** Highly active. Repurchased $450 million of stock in 2025. - **Dividend policy:** The company pays a regular quarterly dividend of $0.72 per share ($2.88 annualised), representing a payout ratio of approximately 15-20% of free cash flow. ## Cash Flow Characteristics - **Operating cash flow conversion:** Strong. OCF to Net Income typically runs at 1.2x to 1.5x due to high depreciation and amortisation add-backs. - **Free cash flow margin:** 8% to 9% ($1.21 billion FCF on $13.95 billion revenue in 2025). - **Major non-cash items:** Depreciation, amortisation of acquired intangibles, and stock-based compensation. - **Working capital cash flow impact:** Generally a use of cash during periods of high organic growth due to the build-up of accounts receivable. - **Capex intensity:** Moderate (under 5% of revenue), allowing for strong free cash flow generation. - **Cash tax rate vs. GAAP effective tax rate:** Cash taxes are generally lower than the GAAP effective rate due to accelerated depreciation on laboratory equipment and amortisation of tax-deductible goodwill from historical asset purchases. ## Sheet Structure 1. **Assumptions**: Hardcoded inputs for macroeconomic drivers, segment growth rates, margin profiles, tax rates, and capital allocation policies. 2. **Revenue & Segments**: Detailed build of Diagnostics (Volume and Price/Mix) and BLS (Backlog, Net Orders, Conversion Rate). Must include a specific line for "Intersegment Eliminations" to bridge to consolidated revenue. 3. **Income Statement**: Consolidated view mirroring the 10-K. Includes a bridge from GAAP Operating Income to Adjusted Operating Income (adding back amortisation, restructuring, and special items). 4. **Balance Sheet**: Standard presentation of assets, liabilities, and equity. Must explicitly break out Goodwill, Intangible Assets, and Right-of-Use Lease Assets. 5. **Working Capital Schedule**: DSO, DIO, and DPO calculations driving the accounts receivable, inventory, and accounts payable balances. 6. **Cash Flow Statement**: Three-statement reconciliation. Net Income to OCF, less Capex to arrive at Free Cash Flow. Includes sections for M&A spend, dividends, and share repurchases. 7. **Debt & Interest Schedule**: Tranche-by-tranche breakdown of senior notes, calculating interest expense and tracking debt paydown or issuance. 8. **DCF Valuation**: Unlevered free cash flow build, WACC calculation, terminal value calculation, and implied share price output. ## Key Financial Relationships 1. `Dx Revenue = Prior Year Dx Revenue * (1 + Organic Volume Growth + Acquired Volume Growth + Price/Mix Growth)` 2. `BLS Net Orders = BLS Revenue * Book-to-Bill Ratio` 3. `BLS Ending Backlog = Beginning Backlog + Net Orders - BLS Revenue - Cancellations/FX Adjustments` 4. `BLS Revenue = Beginning Backlog * Backlog Conversion Rate` 5. `Consolidated Revenue = Dx Revenue + BLS Revenue - Intersegment Eliminations` 6. `Gross Profit = Consolidated Revenue - Cost of Revenues (Personnel + Supplies + Logistics)` 7. `Adjusted Operating Income = GAAP Operating Income + Amortisation + Restructuring Charges + Special Items` 8. `Accounts Receivable = (Consolidated Revenue / 365) * DSO` 9. `Free Cash Flow = Operating Cash Flow - Capital Expenditures` 10. `Net Debt = Total Debt - Cash and Cash Equivalents` 11. `Interest Expense = Average Total Debt * Weighted Average Interest Rate` 12. `Ending Share Count = Beginning Share Count - (Share Repurchase Spend / Average Share Price)` ## Cross-Sheet Dependencies The **Assumptions** sheet dictates the drivers in the **Revenue & Segments** sheet. The segment revenues aggregate into the **Income Statement** top line. The **Income Statement** generates Net Income, which is the starting point for the **Cash Flow Statement**. The **Working Capital Schedule** calculates changes in operating assets and liabilities, feeding into Operating Cash Flow. The **Cash Flow Statement** determines the ending cash balance and debt requirements, which feed the **Balance Sheet**. The **Debt & Interest Schedule** calculates interest expense based on the debt balances, feeding back into the **Income Statement**. This creates a circular reference between interest expense, net income, cash flow, and debt balances, which requires a circuit breaker or iterative calculation toggle. ## Sign Convention - **Revenues, Assets, and Equity:** Displayed as positive numbers. - **Expenses (COGS, SG&A, Interest):** Displayed as positive numbers in their specific schedules, but subtracted in the Income Statement totals. - **Liabilities:** Displayed as positive numbers on the Balance Sheet. - **Cash Flow Statement:** Cash inflows are positive. Cash outflows (Capital Expenditures, Dividends Paid, Share Repurchases, Debt Repayment) must be strictly negative. ## Things Most Likely to Go Wrong - **Spin-off Comparability:** The company spun off Fortrea in mid-2023. Historical data prior to 2023 includes this business. The model must use "Continuing Operations" figures for historical benchmarking to ensure comparability. - **Intersegment Eliminations:** Diagnostics and BLS frequently perform services for one another. If the model simply adds Dx and BLS revenue without subtracting intersegment eliminations, consolidated revenue will be overstated. - **Adjusted vs. GAAP Metrics:** Labcorp heavily promotes Adjusted EPS and Adjusted Operating Income. The model must explicitly forecast the add-backs (amortisation, restructuring) to bridge GAAP to Adjusted figures, otherwise valuation multiples will look artificially inflated. - **LaunchPad Savings:** The company frequently cites "LaunchPad" cost savings. These are real operational improvements, but the costs to achieve them are often excluded from adjusted metrics. The cash flow statement must capture the actual cash outflow for these restructuring initiatives. - **PAMA Cuts:** Medicare pricing cuts can cause sudden step-downs in Dx Price/Mix. Straight-lining historical price/mix growth will ignore statutory reimbursement risks. - **Foreign Exchange:** BLS revenue is generated globally. The model should note that reported revenue growth includes FX impacts, which can swing results by 1-2% annually. - **Working Capital Timing:** Labcorp's free cash flow can swing by hundreds of millions of dollars between quarters purely due to the timing of payroll and payer collections. Annual figures are much more reliable than quarterly annualisations. - **Share Count Reduction:** The company aggressively repurchases shares. Failing to forecast the declining share count will result in understated EPS projections. ## Validation Checks - "Consolidated Revenue must exactly equal Dx Revenue + BLS Revenue - Intersegment Eliminations." - "Gross margin should remain within the 27.0% to 30.0% historical band; flag if outside this range." - "Free Cash Flow should align with management guidance of $1.24 billion to $1.36 billion for 2026." - "Adjusted EPS for 2026 should calculate to between $17.55 and $18.25 based on default assumptions." - "Capex as a percentage of revenue must remain between 3.5% and 4.5%." - "Debt/EBITDA leverage ratio should not exceed 2.5x, aligning with the company's investment-grade rating targets." - "The Balance Sheet must balance: Total Assets = Total Liabilities + Shareholders' Equity in every forecast period." - "Dividend payout ratio should remain between 15% and 25% of Free Cash Flow." ## Key Assumptions (Default Values) | Assumption | Default Value | Unit | Rationale | |---|---|---|---| | Dx Volume Growth | 2.5 | % | Aligns with historical organic volume growth and aging population trends. | | Dx Price/Mix Growth | 1.5 | % | Reflects shift to higher-value specialty testing, partially offset by Medicare cuts. | | BLS Revenue Growth | 6.0 | % | Midpoint of historical growth, reflecting steady pharma R&D demand. | | Intersegment Eliminations | 0.5 | % of Total | Historical average of cross-segment service billing. | | Gross Margin | 28.5 | % | 3-year average reflecting post-COVID normalisation and LaunchPad savings. | | SG&A Margin | 13.5 | % | Historical average, highly fixed headcount base. | | D&A Margin | 4.5 | % | Reflects heavy amortisation from historical acquisitions. | | Effective Tax Rate | 23.5 | % | Management guidance and recent historical average. | | DSO (Days Sales Outstanding) | 50 | Days | Standard collection cycle for complex healthcare payer billing. | | DIO (Days Inventory Outstanding) | 18 | Days | Efficient inventory management of lab supplies and reagents. | | DPO (Days Payable Outstanding) | 40 | Days | Standard vendor payment terms. | | Capex % of Revenue | 3.8 | % | Historical average, supporting maintenance and new central lab builds. | | Annual Share Repurchases | 450 | $ Millions | Matches actual 2025 capital allocation execution. | | Annual Dividend per Share | 2.88 | $ | Based on the $0.72 quarterly dividend declared in early 2026. | | Cost of Debt | 4.8 | % | Weighted average interest rate on existing senior notes. | | WACC | 8.0 | % | Standard discount rate for large-cap healthcare services. | | Terminal Growth Rate | 2.0 | % | Long-term GDP and healthcare spending growth proxy. | ## Data Sources & Benchmarks - **Filings:** SEC EDGAR (Labcorp 10-K, 10-Q, 8-K filings), Labcorp Investor Relations website (Supplemental Financial Information presentations). - **Key Peers:** Quest Diagnostics (DGX) for the Diagnostics segment; IQVIA (IQV) and ICON plc (ICLR) for the Biopharma Laboratory Services segment. - **Industry Data:** Centers for Medicare & Medicaid Services (CMS) for Clinical Laboratory Fee Schedule (CLFS) updates and PAMA regulations. - **Consensus Estimates:** FactSet or Bloomberg for forward-looking EPS and revenue consensus to validate model outputs against street expectations. ## Sources - Labcorp Q4 2025 Earnings Release and 2026 Guidance (February 17, 2026) - Labcorp 2024 Annual Report on Form 10-K - Labcorp Q3 2025 Supplemental Financial Information - Labcorp Q4 2024 Supplemental Financial Information --- ## Frequently asked questions ### What services does Labcorp (LH) provide? Labcorp is a global life sciences company offering comprehensive clinical laboratory and end-to-end drug development services. It operates extensive testing facilities and patient service centers, serving doctors, hospitals, pharmaceutical companies, and researchers. ### What are the primary revenue drivers for Labcorp's business? Labcorp's revenue is primarily driven by its Diagnostics Laboratories (Dx) segment, which accounts for approximately 77% of total revenue, and its Biopharma Laboratory Services (BLS) segment, contributing 23%. Profitability is highly sensitive to diagnostic testing volumes, requisition throughput, and the conversion of its Biopharma backlog. ### What is Labcorp's typical capital expenditure as a percentage of revenue? Labcorp's capital expenditure typically ranges from 3.5% to 4.5% of its revenue. This capex is roughly split equally between maintenance for existing lab equipment and facilities, and growth investments like new central lab facilities and digital pathology. ### How does Labcorp's working capital profile impact its operations? Labcorp maintains a positive net working capital, primarily driven by an extended collection cycle from healthcare payers, with Days Sales Outstanding (DSO) between 45 to 55 days. This positive working capital is crucial for funding the company's growth initiatives. ### What key factors does a financial model for Labcorp (LH) consider for valuation? A comprehensive equity valuation model for Labcorp assesses how changes in diagnostic testing volumes, Medicare pricing dynamics, and Biopharma Laboratory Services backlog conversion impact the company's intrinsic value. These factors are critical for projecting free cash flow generation. ### What is Labcorp's strategy regarding mergers and acquisitions? Labcorp is a serial bolt-on acquirer, routinely purchasing hospital outreach laboratories and regional independent labs to increase market density. The company also targets specialty testing acquisitions, typically paying 8x to 12x EV/EBITDA post-synergies. [Interactive forecast calculator](https://finamodel.com/companies/labcorp/forecast)